Skip to content

Dogwood Therapeutics, Inc.: 10-Q filed 2025-11-07

What Dogwood Therapeutics, Inc. reported in its quarterly report filed 2025-11-07 (fiscal Q3 2025): 44 published measures, 125 facts as tagged in accession 0001104659-25-108169.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-07
Fiscal period
fiscal Q3 2025
Accession
0001104659-25-108169 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Dogwood Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3091,992,613USD
At 2024-12-3194,308,246USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3014,607,504USD
At 2024-12-3130,027,223USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-307,258,152USD
At 2025-06-306,878,599USD
At 2025-03-317,086,931USD
At 2024-12-31-10,124,339USD
At 2024-09-30949,431USD
At 2024-06-303,135,813USD
At 2024-03-312,654,528USD
At 2023-12-313,806,894USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3010,126,710USD
At 2024-12-3114,847,949USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-15,744,616USD92
2025-01-01 to 2025-09-30-30,476,921USD273
2025-04-01 to 2025-06-30-3,807,353USD91
2025-01-01 to 2025-03-31-10,924,952USD90
2024-07-01 to 2024-09-30-2,280,684USD92
2024-01-01 to 2024-09-30-4,621,852USD274
2024-04-01 to 2024-06-30-1,049,833USD91
2024-01-01 to 2024-03-31-1,291,335USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-11,981,464USD273
2024-01-01 to 2024-09-30-2,659,297USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-307,252,245USD273
2024-01-01 to 2024-09-301,382,170USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-104,295,867USD
At 2024-12-31-73,818,946USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,919,433shares92
2025-01-01 to 2025-09-301,761,237shares273
2024-07-01 to 2024-09-301,110,317shares92
2024-01-01 to 2024-09-30932,872shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,919,433shares92
2025-01-01 to 2025-09-301,761,237shares273
2024-07-01 to 2024-09-301,110,317shares92
2024-01-01 to 2024-09-30932,872shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-8.2USD/shares92
2025-01-01 to 2025-09-30-18.02USD/shares273
2024-07-01 to 2024-09-30-2.05USD/shares92
2024-01-01 to 2024-09-30-4.95USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-8.2USD/shares92
2025-01-01 to 2025-09-30-18.02USD/shares273
2024-07-01 to 2024-09-30-2.05USD/shares92
2024-01-01 to 2024-09-30-4.95USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-3015,293USD
At 2024-12-3116,811USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-30197,782USD273
2024-01-01 to 2024-09-30382,219USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-15,809,125USD92
2025-01-01 to 2025-09-30-24,162,166USD273
2024-07-01 to 2024-09-30-2,301,172USD92
2024-01-01 to 2024-09-30-4,685,097USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3011,655,377USD
At 2024-12-3116,544,462USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-302,596,809USD
At 2024-12-313,176,336USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-30584,602USD
At 2024-12-311,231,805USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2025-09-3012,209,591USD
At 2024-12-3111,812,476USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-3015,809,125USD92
2025-01-01 to 2025-09-3024,162,166USD273
2024-07-01 to 2024-09-302,301,172USD92
2024-01-01 to 2024-09-304,685,097USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-3014,521,342USD92
2025-01-01 to 2025-09-3019,528,283USD273
2024-07-01 to 2024-09-30535,162USD92
2024-01-01 to 2024-09-301,214,964USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-302,293,162shares
At 2024-12-311,332,178shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3010,126,710USD
At 2024-12-3114,847,949USD
At 2024-09-302,039,819USD
At 2023-12-313,316,946USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3073,158,686USD
At 2024-12-3167,856,589USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-09-30-1,636,135USD
At 2024-12-31-3,862,987USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30174,008USD
At 2024-12-31205,837USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30174,778USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-09-3019,005USD
At 2024-12-3118,387USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-09-303,712USD
At 2024-12-311,576USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-09-3067,919,601USD
At 2024-12-3165,710,527USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-3115,381,077USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-301,957,641USD
At 2024-12-311,894,835USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-301,528,667USD
At 2024-12-311,696,513USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2025-09-3011,890,483USD
At 2024-12-3111,314,925USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-15,746,052USD92
2025-01-01 to 2025-09-30-30,287,666USD273
2024-07-01 to 2024-09-30-2,280,684USD92
2024-01-01 to 2024-09-30-4,621,852USD274

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-30,476,921USD273
2024-01-01 to 2024-09-30-4,621,852USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-17,113,462USD92
2025-01-01 to 2025-09-30-28,250,069USD273
2024-07-01 to 2024-09-30-2,280,684USD92
2024-01-01 to 2024-09-30-4,621,852USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-15,744,616USD92
2025-01-01 to 2025-09-30-31,733,583USD273
2024-07-01 to 2024-09-30-2,280,684USD92
2024-01-01 to 2024-09-30-4,621,852USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,287,783USD92
2025-01-01 to 2025-09-304,633,883USD273
2024-07-01 to 2024-09-301,766,010USD92
2024-01-01 to 2024-09-303,470,133USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-09-302,063USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-07-01 to 2025-09-3063,073USD92
2025-01-01 to 2025-09-30-6,125,500USD273
2024-07-01 to 2024-09-3020,488USD92
2024-01-01 to 2024-09-3063,245USD274

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,436USD92
2025-01-01 to 2025-09-30189,255USD273
2024-07-01 to 2024-09-300USD92
2024-01-01 to 2024-09-300USD274

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-07-01 to 2025-09-3026,283USD92
2025-01-01 to 2025-09-3089,443USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-651,572USD273
2024-01-01 to 2024-09-30343,049USD274

Inspect the source

Entity
Dogwood Therapeutics, Inc. / CIK 0001818844
Captured
2026-09-21T17:28:47.393Z
SEC response SHA-256
f281da32357cf25dc41174624e31afea543fa55e9784845d4d35990b5ae1dd70

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001818844.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))